Cardium Reports on Exchange Listing With NYSE Alternext US (PR Newswire via Yahoo! Finance)
Cardium Therapeutics reported notification from the staff of its current listing exchange indicating that the company is currently considered to be noncompliant with certain listing requirements of the NYSE Alternext US LLC .

FDA Advisory Committee Unanimously Recommends Approval For New Ophthalmic Product Enabled By InSite's DuraSite ... (Medical News Today)
InSite Vision Incorporated (AMEX:ISV) announced that the U.S. Food and Drug Administration (FDA) Dermatologic and Ophthalmic Drugs Advisory Committee has voted unanimously to recommend approval of Bausch & Lomb's besifloxacin ophthalmic suspension, 0.6%, for the treatment of bacterial conjunctivitis, a product that utilizes InSite Vision's DuraSite patented drug delivery system.